Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming - Report - MDSpire
Advertisement
Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming
Clinical Report: Metabolic Competition in the Glioblastoma Microenvironment
Background
Glioblastoma (GBM) is the most lethal primary brain tumor, with a median survival of 14 to 16 months despite aggressive treatment. The tumor microenvironment (TME) is characterized by significant immunosuppression, largely due to metabolic competition among GBM cells and immune cells. Understanding these dynamics is crucial for developing effective therapeutic strategies.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
GBM cells and immunosuppressive myeloid cells rely on glucose and glutamine for their survival and function.
Aerobic glycolysis in GBM cells produces lactate, which polarizes macrophages toward immunosuppressive phenotypes.
Disruption of glucose and glutamine metabolism can reprogram the immunosuppressive myeloid compartment while preserving T cell fitness.
Pharmacological ketosis elevates beta-hydroxybutyrate, enhancing T cell effector function.
Mebendazole is suggested as a potential repurposing candidate with preclinical survival benefits in GBM.
Clinical Implications
Targeting metabolic pathways in the GBM microenvironment may provide new avenues for enhancing anti-tumor immunity.
Conclusion
The competitive dynamics of the glioblastoma microenvironment present significant challenges to effective treatment.
Travis Nemkov and Angelo D’Alessandro discuss how molecular profiling in elite athletes could inform personalized exercise, healthy aging, and cancer recovery
